<DOC>
	<DOCNO>NCT01558011</DOCNO>
	<brief_summary>This open-label , non-comparative phase II study sequential capecitabine plus oxaliplatin follow docetaxel plus capecitabine patient unresectable gastric adenocarcinoma .</brief_summary>
	<brief_title>Using Genetic Polymorphisms Predict Efficacy Toxicity - A Gastric Adenocarcinoma Study</brief_title>
	<detailed_description>There two primary objective different step . In first step , primary objective study investigate objective response rate patient receive sequential capecitabine plus oxaliplatin follow docetaxel plus capecitabine patient unresectable gastric adenocarcinoma . In second step , primary objective study screen predictive biomarkers three different chemotherapeutic drug also investigate objective response rate patient receive sequential capecitabine plus oxaliplatin follow docetaxel plus capecitabine patient unresectable gastric adenocarcinoma .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Pathologically confirm gastric adenocarcinoma . At least one measurable lesion nonirradiated area . No prior exposure systemic chemotherapy advance gastric cancer . For adjuvant chemotherapy curative gastrectomy , last dose previous adjuvant chemotherapy least 6 month start treatment . Age &gt; 20 year old . ECOG Performance Status 2 . Life expectancy great 12 week . Adequate bone marrow function : absolutely neutrophil count 1.5 x 109/L WBC 4 x 109/L ; Hemoglobin &gt; 9 g/dl ; platelet count 100 x 109/L . Adequate liver function : ALT &amp; AST 2.5 x ULN without liver metastasis 5 x ULN hepatic metastasis . Alkaline phosphatase 2.5 x ULN without liver metastasis 5 x ULN , hepatic bone metastasis . Bilirubin &lt; 2 x ULN Adequate renal function : Creatinine &lt; 1.5 x ULN . Patients must accessible treatment followup participate center . Patient receive concurrent radiotherapy , chemotherapy experimental therapy . ( Previous radiotherapy allowable last dose give 2 week protocol treatment ) . Major surgery within two week prior enter study . Patients CNS metastasis , include clinical suspicion . Patients active uncontrolled infection . Patients cardiac arrhythmia myocardial infarction history 6 month entry . Patients clinically detectable peripheral neuropathy &gt; 2 CTC criterion Patients concomitant illness might aggravate chemotherapy . Patients pregnant breast feeding . Other concomitant previously malignancy within 5 yr except situ cervix cancer squamous cell carcinoma skin treat surgery . Patients hypersensitivity component chemotherapeutic regimen . Mental status fit clinical trial Can take study medication orally</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>gastric adenocarcinoma</keyword>
	<keyword>Capecitabine oxaliplatin ( XELOX )</keyword>
	<keyword>Docetaxel capecitabine ( TX )</keyword>
	<keyword>Using genetic polymorphism</keyword>
	<keyword>drug metabolism immunohistochemical stain</keyword>
	<keyword>predict efficacy</keyword>
</DOC>